The New York State Medicaid Prescriber Education Program: The Role of Palivizumab in RSV Bronchiolitis


The New York State Medicaid Prescriber Education Program: The Role of Palivizumab in RSV Bronchiolitis 


This program has been designed as an on-line webinar and interactive algorithm for pediatricians and family medicine physicians. The goals of this program are:

  • To improve understanding and/or awareness with respect to:
    • RSV epidemiology, virology, and prevention
    • RSV morbidity and mortality
    • RSV season and risk factors
    • the economic impact of RSV disease and RSV prophylaxis 
  • to improve competence so as to positively impact patient outcomes by optimizing RSV prophylaxis of high-risk patients in a cost-effective manner

This module will take approximately 45-60 minutes to complete, and may be completed in sections. 

Learning Objectives

After viewing this CME activity, participants should be able to:

  • Discuss the incidence of RSV hospitalization and death among infants
  • Recognize the signs/symptoms of RSV bronchiolitis
  • Identify the season/months during which RSV infection peaks
  • Define the role of palivizumab in the prevention of RSV bronchiolitis hospitalization/complications
  • Identify high-risk populations and assess who should and who should not receive RSV prophylaxis based upon current AAP guidelines and primary literature references
  • Design a palivizumab regimen for RSV prophylaxis in a high-risk patient

Editorial Board


William A. Prescott Jr, PharmD
Clinical Assistant Professor
University at Buffalo Department of Pharmacy Practice Residency Director
School of Pharmacy and Pharmacuetical Sciences
University at Buffalo, The State University of New York

Luke Probst, PharmD, BCPS
Clinical Assistant Professor
Department of Pediatrics
Department of Medicine
Upstate Medical University, The State University of New York

Disclosure Statement

The Accrediation Council for Continuing Medical Education require disclosure of:

  • Relationships that CME faculty may have with any company whose products or services may be discussed or has a specific interest in the therapeutic area under discussion
  • The absence of such relationships
  • The refusal to reveal such relationships

Having an interest or affiliation with such organization does not necessarily preclude a participant from making a presentation. 

Name Affiliation
William A. Prescott Nothing to Disclose
Luke Probst Nothing to Disclose
Marsha Nelson Nothing to Disclose

Accreditation Statement

The University at Buffalo (UB) School of Medicine and Biomedical Sciences is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Designation Statement

The UB School of Medicine & Biomedical Sciences designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Series Released: 07.01.2011
Series Expires: 07.01.2014